A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

NCT00781885 | Completed Phase 2 Results

• 1 other identifier: BPS-MR-PAH-201
• Study Type: interventional
• Target: 19
• Locations: 3 countries
• Sites: 6

Brief Summary

This study is an international, open-label, multi-center, Phase II, multiple dose, dose-finding study to investigate the safety, tolerability and pharmacokinetic characteristics of BPS-MR tablets in male and female patients with PAH. Patients who meet the inclusion/exclusion criteria will enter the Treatment Phase at a Baseline visit. Patients will begin taking one BPS-MR tablet (60µg) twice daily (b.i.d.) escalating by one tablet b.i.d. each week to a maximum dose of 600µg (ten tablets) b.i.d or until the patient reaches their MTD. Following the achievement of the MTD, patients will be down-titrated off BPS-MR in weekly one tablet b.i.d. decrements. Patients may, alternatively, elect to continue taking the study drug at their MTD in a separate open-label extension study.

Conditions

Pulmonary Arterial Hypertension

Outcome Measures

Primary Outcomes (1)

• Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration.

  10 Weeks

Secondary Outcomes (11)

• Number of Participants That Reported at Least One Treatment-Emergent Adverse Event (TEAE)

  19 Weeks

• Change in Body Mass Index (BMI) From Baseline to Week 19

  Baseline and 19 weeks

• Change in Weight From Baseline to Week 19

  Baseline and 19 weeks

• Change in Heart Rate From Baseline to Week 19

  Baseline and 19 weeks

• Change in Body Temperature From Baseline to Week 19

  Baseline and 19 weeks

Interventions

Beraprost sodium modified release DRUG

Tablets 60mcg

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Is male or female between the ages of 18 and 75 years of age, inclusive;
• Has either idiopathic or familial PAH, PAH associated with collagen vascular disease, or PAH induced by anorexigens;
• Is clinically stable, as determined by the investigator;
• Has previously undergone a cardiac catheterization which is consistent with PAH, specifically PAPm ≥25 mmHg (at rest), PCWP (or left ventricular end diastolic pressure) ≤15 mmHg, and PVR \>3 wood units;
• Has been on a course of an endothelin receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5) or the combination for at least 90 days at the time of the Baseline visit;
• Has an unencouraged six-minute walk distance (6MWD) between 300 and 600 meters at the Screening visit;
• Is able to communicate effectively with study personnel;
• Is considered to be reliable, willing, cooperative and compliant with the study protocol requirements;
• Provides voluntary, written informed consent before participating in the study;
• Is, if female, physiologically incapable of childbearing or is practicing an acceptable method of birth control (i.e., surgical sterilization, approved hormonal contraceptives, barrier methods \[such as a condom or diaphragm\] used with a spermicide, or an intrauterine device).

You may not qualify if:

• Has pulmonary venous hypertension, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, severe chronic obstructive pulmonary disease, pulmonary hypertension related to congenital heart disease, or chronic thromboembolic pulmonary hypertension;
• Is pregnant or lactating;
• Has a known intolerance to beraprost sodium or prostanoids;
• Has a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs;
• Current use of tobacco products;
• Known history of syncope;
• Has had a change in or discontinued any PAH medication (with the exception of anticoagulants) within 30 days prior to the Baseline visit;
• Has received any prostanoid therapy within the 30 days prior to the Baseline visit or be scheduled to receive additional prostanoid therapy during the study except for acute vasodilatory testing;
• Has received any investigational medication within 30 days prior to the Baseline visit or be scheduled to receive another investigational drug during the course of this study;
• In the opinion of the investigator, may be unable to comply with the study protocol;
• Has donated blood or plasma or has lost a volume of blood \>450 mL within six weeks prior to the Baseline visit.
• Has an ongoing hemorrhagic condition (e.g. upper digestive track hemorrhage, hemoptysis, etc.) or has a pre-existing condition that, in the investigator's judgement, may increase the risk for developing hemorrhage during the study (e.g. hemophilia). However, transient hemorrhage (e.g. epistaxis, normal menstrual bleeding, gingival bleeding, hemorrhoidal hemorrhage, etc.) would not preclude enrollment

Sponsors & Collaborators

• Lung Biotechnology PBC: lead

Study Sites (6)

Harbor-UCLA Medical Center

Torrance, California, 90502, United States

Location

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States

Location

UTSW Medical Center

Dallas, Texas, 8550, United States

Location

Universite Libre de Bruxelles, Hospital Erasme

Brussels, Belgium

Location

Gastuiberg University Hospital

Leuven, 3000, Belgium

Location

Mater Misericordiae University Hospital Ltd.

Dublin, Ireland

Location

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Results Point of Contact

• Title: Lung Biotechnology PBC Study Director
• Organization: Lung Biotechnology PBC

301-608-9292

Study Officials

• Ted Staub, MS, MEng

  Study Sponsor

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 27, 2008
• First Posted: October 29, 2008
• Study Start: January 31, 2009
• Primary Completion: September 30, 2010
• Study Completion: September 30, 2010
• Last Updated: June 9, 2020
• Results First Posted: June 9, 2020

Record last verified: 2020-06

Locations

US (3); BE (2); IE (1)